Skip to main content
Figure 1 | BMC Neurology

Figure 1

From: Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

Figure 1

Natalizumab PML risk estimates by treatment epoch[37]. The observed clinical trial PML incidence in patients who received a mean of 17.9 monthly doses of natalizumab was 1.00 per 1000 natalizumab-treated patients (95% CI 0.20–2.80) [36]. The post-marketing rate is calculated as the number of PML cases in patients who have had at least one dose of natalizumab. Incidence estimates by treatment epoch are calculated based on natalizumab exposure through 30 April 2013 and 359 confirmed cases as of 6 May 2013. The incidence for each epoch is calculated as the number of PML cases divided by the number of patients exposed to natalizumab.

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us